Rheumatoid Arthritis Research Today is a free monthly online journal that collates and summarizes the latest research about Rheumatoid Arthritis, including details on treatment, symptoms, causes, medication.

Volume 8 (2011), Issue 3 (March)

1. Parity, time since last live birth and long-term functional outcome: a study of women participating in the Norfolk Arthritis Register.
   Ann Rheum Dis, 70(4): 642-5. [Abstract] [Full-text]
2. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
   Ann Rheum Dis, 70(4): 583-9. [Abstract] [Full-text]
3. Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort.
   Ann Rheum Dis, 70(4): 611-5. [Abstract] [Full-text]
4. Tumour necrosis factor alpha-driven IL-32 expression in rheumatoid arthritis synovial tissue amplifies an inflammatory cascade.
   Ann Rheum Dis, 70(4): 660-7. [Abstract] [Full-text]
5. Effectiveness of initial treatment allocation based on expert opinion for prevention of rapid radiographic progression in daily practice of an early RA cohort.
   Ann Rheum Dis, 70(4): 634-7. [Abstract] [Full-text]
6. Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden.
   Ann Rheum Dis, 70(4): 624-9. [Abstract] [Full-text]
7. Mutations of the cystic fibrosis gene in patients with bronchiectasis associated with rheumatoid arthritis.
   Ann Rheum Dis, 70(4): 653-9. [Abstract] [Full-text]
8. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis.
   Ann Rheum Dis, 70(4): 576-82. [Abstract] [Full-text]
9. Parity, time since last live birth and long-term functional outcome: a study of women participating in the Norfolk Arthritis Register.
   Ann Rheum Dis, 70(4): 642-5. [Abstract] [Full-text]
10. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Ann Rheum Dis, 70(4): 583-9. [Abstract] [Full-text]
11. Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort.
    Ann Rheum Dis, 70(4): 611-5. [Abstract] [Full-text]
12. Tumour necrosis factor alpha-driven IL-32 expression in rheumatoid arthritis synovial tissue amplifies an inflammatory cascade.
    Ann Rheum Dis, 70(4): 660-7. [Abstract] [Full-text]
13. Effectiveness of initial treatment allocation based on expert opinion for prevention of rapid radiographic progression in daily practice of an early RA cohort.
    Ann Rheum Dis, 70(4): 634-7. [Abstract] [Full-text]
14. Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden.
    Ann Rheum Dis, 70(4): 624-9. [Abstract] [Full-text]
15. Mutations of the cystic fibrosis gene in patients with bronchiectasis associated with rheumatoid arthritis.
    Ann Rheum Dis, 70(4): 653-9. [Abstract] [Full-text]
16. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis.
    Ann Rheum Dis, 70(4): 576-82. [Abstract] [Full-text]
17. Attenuation of oxidative stress by allylpyrocatechol in synovial cellular infiltrate of patients with Rheumatoid Arthritis.
    Free Radic Res, 45(5): 518-26. [Abstract] [Full-text]
18. The sparkle of the eye: the impact of ocular surface wetness on corneal light reflection.
    Am J Ophthalmol, 151(4): 691-696.e1. [Abstract] [Full-text]
19. Effects of adalimumab therapy on disease activity and interferon-γ-mediated biochemical pathways in patients with rheumatoid arthritis.
    Autoimmunity, 44(3): 235-42. [Abstract] [Full-text]
20. NFKBIL1 confers resistance to experimental autoimmune arthritis through the regulation of dendritic cell functions.
    Scand J Immunol, 73(5): 478-85. [Abstract] [Full-text]
21. Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis.
    Autoimmunity, 44(3): 243-52. [Abstract] [Full-text]
22. The role of Natural Killer cells in the pathogenesis of rheumatoid arthritis: major contributors or essential homeostatic modulators?
    Immunol Lett, 136(2): 115-21. [Abstract] [Full-text]
23. Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses.
    Curr Opin Rheumatol, 23(3): 282-7. [Abstract] [Full-text]
24. Pathophysiology of rheumatoid arthritis.
    Curr Opin Rheumatol, 23(3): 233-40. [Abstract] [Full-text]
25. New therapies in the management of rheumatoid arthritis.
    Curr Opin Rheumatol, 23(3): 245-51. [Abstract] [Full-text]
26. Drug-free remission: is it already possible?
    Curr Opin Rheumatol, 23(3): 266-72. [Abstract] [Full-text]
27. The value of blocking IL-6 outside of rheumatoid arthritis: current perspective.
    Curr Opin Rheumatol, 23(3): 273-7. [Abstract] [Full-text]
28. Monitoring rheumatoid arthritis.
    Curr Opin Rheumatol, 23(3): 252-8. [Abstract] [Full-text]
29. Genetics of rheumatoid arthritis: time for a change!
    Curr Opin Rheumatol, 23(3): 227-32. [Abstract] [Full-text]
30. Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011?
    Curr Opin Rheumatol, 23(3): 288-92. [Abstract] [Full-text]
31. Nonpharmacological treatment of rheumatoid arthritis.
    Curr Opin Rheumatol, 23(3): 259-64. [Abstract] [Full-text]
32. Treatment strategies in recent onset rheumatoid arthritis.
    Curr Opin Rheumatol, 23(3): 241-4. [Abstract] [Full-text]

© 2004-2012 Rheumatoid Arthritis Research Today. All Rights Reserved.